SOURCE-LINKED INTELLIGENCE

Rerouting mRNA for in vivo chimeric antigen receptor immune cell therapy

CORDIS · observation · Publication date unknown

d of natural phospho(lipids), ionizable cationic materials and apolipoprotein A1 (apoA1), and containing mRNA – and screen barcoded aNPs’ ability to functionally deliver mRNA to immune cells in vivo. Machine learning analysis will provide lead formulations for in vivo CAR monocyte/macrophage (CAR M) proof-of-concept therapeutic studies in a solid tumor mouse model. KO2: Using proprietary apoA1-nanobody fusion protein technology, we will screen targeted mRNA-aNPs’ ability to induce functional gene expression in specific immune cells in vivo. Lead aNP-mRNA formulations will be used for in vivo CAR T proof-of-concept therapeutic studies in a hematological mouse tumor model. This Program’s successful completion will yield a unique, versatile nanomedicine approach that can be employed to induce in vivo CAR immune cell therapy for cancer treatment, with significant translational potential and pertinency for applications in non-malignant diseases such as autoimmune disorders and cardiovascular disease. Chimeric antigen receptor, messenger RNA, nanoparticle, apolipoprotein, fusion protein, m

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

2000000

unit

EUR